For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented.
In a clinical study from the Swedish University of Agricultural Sciences and the University of Gothenburg, OA horses that received a novel drug treatment became completely free from lameness, with a simultaneous impediment of the joint tissue degradation. Exploring this drug treatment for human OA intervention is now being considered.
Osteoarthritis (OA) is an inflammatory-whole joint disease which affects both animals and humans. It is the most common cause of lameness and joint pain in horses. Racehorses often become lame early in their careers, and every year a large number of horses retire due to the disease.
A new drug with potential cure
The new potential treatment for OA is a result of a long-term collaboration of researchers at the Swedish University of Agricultural Sciences and the University of Gothenburg, resulting in a series of basic science publications. Through cell culture studies, the researchers were able to evaluate and present a drug combination consisting of a local anesthetic drug and an anti-inflammatory drug (sildenafil), in extremely low concentrations, that when combined with glucose can restore the derailed cartilage cells (i.e. chondrocytes) in OA horses.
“We have successfully demonstrated the drugs’ potential in receding inflammation and in restoring derailed chondrocytes from OA horses. Such restored cartilage cells began to produce more matrix molecules, which are important building blocks of cartilage tissue. This further strengthens the drug combinations’ potential to cure osteoarthritis,” said Elisabeth Hansson, professor at the Sahlgrenska Academy, University of Gothenburg.
New diagnosis method
The research team developed assays to screen horses’ synovial fluid from the joints and diagnose OA much earlier, even before clinical indications of OA. This was indispensable for clinically testing the drug in horses. The current clinical study, published in the journal Osteoarthritis and Cartilage Open, uses these assay methods both to diagnose the disease and to measure the efficacy of the new drug treatment.
Two biomarkers are elevated in both synovial fluid and blood, in the horses with OA. These biomarkers have been crucial in the development of the new drug treatment.
“With the aid of these biomarkers, we can now diagnose the disease in an early stage (which was not possible previously), measure the efficacy of the drug and also screen for the drugs’ side effects,” said Eva Skiöldebrand, professor at the Swedish University of Agricultural Sciences.
Randomized clinical trial
In this study, the new drug combination was tested in a randomized triple-blinded controlled clinical trial. The study was conducted at Hallands Djursjukhus (Kungsbacka Hästklinik). The principal investigator, Kristin Abrahamsson-Aurell, was responsible for the study with veterinarian Cecilia Grahn as the treating veterinarian. Twenty lame trotters with mild radiological changes in the carpal joint were included in the study. The horses were randomized into groups for treatment with the novel drug combination or with a standard treatment (the drug Celeston bifas). The horses were followed up for 60 days after treatment.
“The horses treated with the new drug combination became free from lameness. The drug treatment efficiently lowered the analyzed biomarkers’ levels in the synovial fluid when compared to the horses that received the control substance. The drug intervention did not cause any side effects in this study. Moreover, several of the treated horses remained sound during the follow up period, which gives great hope for the future of the drug as a disease-modifying agent. This will have a tremendous positive impact on horse welfare,” said Skiöldebrand.
Potential for treatment in humans
In Sweden, OA is also the most common joint disease in humans, especially among the elderly. About one in four people over the age of 45 develop osteoarthritis. Currently, there is no cure for this. Also, the available drugs on the market can only reduce pain and limit inflammation in the joint.
“Horses and humans are genetically very similar. Horses develop OA spontaneously, which makes the horse an excellent model for studies of OA in humans. Additionally, the biomarkers that were identified and evaluated in the clinical trial are identical in horses and humans. Therefore the biomarkers and the analytical methods are equally relevant in human OA,” Skiöldebrand said.
The research team has a patent for the new drug combination and aims to commercialize it as a licensed drug for horses with OA, starting in Sweden. They will now also seek authorization to conduct a clinical trial of the drug treatment in humans.
Partnering 2030: The Biotech Perspective 2023
